Volume 29, Issue 4 (Avicenna Journal of Clinical Medicine-Winter 2023)                   Avicenna J Clin Med 2023, 29(4): 197-203 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Mohammadi Pasand F, Jamshidi M, Roshan S D, Ghasemi Basir H R. Evaluation of Variant Lymphocyte Count in Peripheral Blood Smear of Patients with Mycosis Fungoides and Its Comparison with the Normal Population. Avicenna J Clin Med 2023; 29 (4) :197-203
URL: http://sjh.umsha.ac.ir/article-1-2573-en.html
1- Department of Dermatology, School of Medicine, Sina Research Center, Hamadan University of Medical Sciences, Hamadan, Iran
2- School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran
3- Department of Pathology, School of Medicine, Sina Research Center, Hamadan University of Medical Sciences, Hamadan, Iran , hrgb2004@yahoo.com
Abstract:   (1090 Views)
Background and Objective: Mycosis fungoides is a neoplastic skin disorder whose underlying cause is not yet fully understood. There are hypotheses about the possible effect of viral agents on the development of mycosis fungoids that have not yet been proven. The present study aimed to evaluate the lymphocyte variant in peripheral blood smear of patients with mycosis fungoides fungoids to determine the possible role of viral agents in the development of mycosis fungoids.
Materials and Methods: In this case-control study, 55 patients with a definite diagnosis of mycosis fungoides based on pathology, clinical and immunological findings (ISCL) were selected by convenience and consecutive sampling method from those referring to referred to Farshchian Hospital (Sina) in Hamadan in 2020 and compared with 55 healthy individuals regarding variant lymphocytes percent of peripheral blood smear.
Results: Patients with mycosis fungoides and the control group were matched in terms of age and gender. In the study of peripheral blood smear in patients with mycosis fungoides and the control group, the mean percentage of eosinophils was 5.35±5.11 and 3.00±2.01 (P=0.043), monocytes were 8.27±4.08 and 3.17±1.57 (P<0.001), neutrophils were 53.38±12.97 and 61.64±13.00 (P=0.001), lymphocytes were 31.67±12.57 and 32.95±12.60 (P=0.597), variant lymphocytes was 24.69±15.58 and 3.60±4.66 (P<0.001), and band cells were 1.75±0.96 and 2.25±0.71 (P=0.368) respectively.
Conclusion: In patients with mycosis fungoides, the percentage of variant lymphocytes was significantly higher than that in the control group, suggesting the role of infectious agents, especially EBV & CMV, in this disease.
Full-Text [PDF 736 kb]   (352 Downloads)    
Type of Study: Original | Subject: Pathology

1. Parker SR, Bethaney JV. Cutaneous T cell lymphoma-mycosis fungoides and Sezary syndrome: an update. G Ital Dermatol Venereol. 2009;144(4):467-85. PMID: 19755952.
2. Pimpinelli N, Olsen EA, Santucci M, Vonderheid E, Haeffner AC, Stevens S, et al. International society for cutaneous lymphoma. Defining early mycosis fungoides. J Am Acad Dermatol. 2005;53(6):1053-63. PMID:16310068. DOI:10.1016/j.jaad.2005.08.057.
3. Evans AV, Scarisbrick JJ, Child FJ, Acland KM, Whittaker SJ, Russell-Jones R. Cutaneous malignant melanoma in association with mycosis fungoides. J Am Acad Dermatol. 2004;50(5):701-5. PMID:15097953. DOI:10.1016/j.jaad. 2003.11.054.
4. Patel SP, Holtermann OA. Mycosis fungoides: an overview. J Surg Oncol. 1983;22(4):221-7. PMID:6834842. DOI:10.1002/jso.2930220403
5. Worobec-Victor SM. Cutaneous T cell lymphoma. N J Med. 1989;86(5):395-400. PMID: 2662058
6. Patterson J, Wick M. Lymphoid infiltrates, lymphoma, and hematopoietic proliferations. AFIP atlas of tumor pathology: Nonmelanocytic tumors of the skin. ARP Press; 2006.
7. Nashan D, Faulhaber D, Ständer S, Luger TA, Stadler R. Mycosis fungoides: a dermatological masquerader. Br J Dermatol. 2007;156(1):1-10. PMID: 17199560. DOI:10.1111/j.1365-2133.2006.07526.x
8. Morales-Suárez-Varela MM, Olsen J, Johansen P, Kaerlev L, Guénel P, Arveux P, et al. Occupational risk factors for mycosis fungoides: a European multicenter case-control study. J Occup Environ Med. 2004;46(3):205-11. PMID:15091282. DOI:10.1097/01.jom.0000116819.01813.8c
9. Whittemore AS, Holly EA, Lee IM, Abel EA, Adams RM, Nickoloff BJ, et al. Mycosis fungoides in relation to environmental exposures and immune response: a case-control study. J Natl Cancer Inst. 1989;81(20):1560-7. PMID:2795681 DOI:10.1093/jnci/81.20.1560
10. Cerroni L. Mycosis fungoides-clinical and histopathologic features, differential diagnosis, and treatment. Semin Cutan Med Surg. 2018;37(1):2-10. PMID: 29719014
11. Wohl Y, Tur E. Environmental risk factors for mycosis fungoides. Curr Probl Dermatol. 2007;35:52-64. PMID: 17641490 DOI: 10.1159/000106410
12. Blaizot R, Ouattara E, Fauconneau A, Beylot-Barry M, Pham-Ledard A. Infectious events and associated risk factors in mycosis fungoides/Sézary syndrome: a retrospective cohort study. Br J Dermatol. 2018;179(6):1322-8. PMID:30098016. DOI: 10.1111/bjd.17073
13. Scarisbrick JJ. Infections in mycosis fungoides and Sézary syndrome are a frequent cause of morbidity and contribute to mortality. What can be done? Br J Dermatol. 2018;179(6):1243-4. PMID: 30508233. DOI: 10.1111/bjd.17194
14. Benton EC, Crichton S, Talpur R, Agar NS, Fields PA, Wedgeworth E, et al. A cutaneous lymphoma inter-national prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome. Eur J Cancer. 2013;49(13):2859-68. PMID:23735705. DOI:10.1016/j.ejca.2013.04.018
15. Pereyo NG, Requena L, Galloway J, Sangüeza OP. Follicular mycosis fungoides: a clinicohistopathologic study. J Am Acad Dermatol. 1997;36(4):563-8. PMID:9092742. DOI:10.1016/s0190-9622(97)70244-5.
16. Cengiz FP, Emiroglu N, Ozkaya DB, Bahali AG, Su O, Onsun N. Prognostic evaluation of neutrophil/lymphocyte ratio in patients with Mycosis Fungoides. Ann Clin Lab Sci. 2017;47(1):25-8. PMID:28249912.
17. Ballanger F, Bressollette C, Volteau C, Planche L, Dreno B. Cytomegalovirus: its potential role in the development of cutaneous T-cell lymphoma. Exp Dermatol. 2009;18(6):574-6. PMID:19320742 DOI:10.1111/j.1600-0625.2008.00817.x
18. Noorali S, Yaqoob N, Nasir MI, Moatter T, Pervez S. Prevalence of mycosis fungoides and its association with EBV and HTLV-1 in Pakistanian patients. Pathol Oncol Res. 2002;8(3):194-9. PMID:12516000 DOI:10.1007/BF03032394.
19. Mirvish ED, Pomerantz RG, Geskin LJ. Infectious agents in cutaneous T-cell lymphoma. J Am Acad Dermatol. 2011;64(2):423-31. PMID:20692726 DOI:10.1016/j.jaad.2009.11.692
20. Morales MM, Olsen J, Johansen P, Kaerlev L, Guénel P, Arveux P, et al. Viral infection, atopy and mycosis fungoides: a European multicentre case-control study. Eur J Cancer. 2003;39(4):511-6. PMID:12751383 DOI:10.1016/s0959-8049(02)00773-6
21. Nahidi Y, Meibodi NT, Ghazvini K, Esmaily H, Hesamifard M. Evaluation of the association between Epstein-Barr virus and Mycosis Fungoides. Indian J Dermatol. 2015;60(3):321. PMID:26120176 DOI:10.4103/0019-5154.156423
22. Amorim GM, Niemeyer-Corbellini JP, Quintella DC, Cuzzi T, Ramos-E-Silva M. Clinical and epidemiological profile of patients with early stage mycosis fungoides. An Bras Dermatol. 2018;93(4):546-52. PMID:30066762 DOI:10.1590/abd1806-4841.20187106
23. Herne KL, Talpur R, Breuer-McHam J, Champlin R, Duvic M. Cytomegalovirus seropositivity is significantly associated with mycosis fungoides and Sézary syndrome. Blood. 2003;101(6):2132-6. PMID:12446446 DOI:10.1182/blood-2002-07-2247
24. Dreno B, Celerier P, Fleischmann M, Bureau B, Litoux P. Presence of Epstein-Barr virus in cutaneous lesions of mycosis fungoides and Sézary syndrome. Acta Derm Venereol. 1994;74(5):355-7. PMID:7817670 DOI:10.2340/0001555574355357.
25. Novelli M, Merlino C, Ponti R, Bergallo M, Quaglino P, Cambieri I, et al. Epstein-Barr virus in cutaneous T-cell lymphomas: evaluation of the viral presence and significance in skin and peripheral blood. J Invest Dermatol. 2009;129(6):1556-61. PMID:19131945 DOI:10.1038/jid.2008.396
26. Celik E. Evaluating complete blood count parameters in early-stage Mycosis Fungoides patients. IJBCS. 2020;9(1):56-64.

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Avicenna Journal of Clinical Medicine

Designed & Developed by : Yektaweb